检索结果-南通市图书馆

The Contribution of the Xpert^® MTB/RIF Assay to the Surv.illance of Drug-Resistant Tuberculosis in the Central African Republic

引用

Journal of Tuberculosis Research 2023年第1期11卷 23-32页

作者： Alain Farra lydie v. danebera Gilles Ngaya Brice M. Yambiyo Alexandre Manirakiza Christian D. Mossoro-Kpinde National Reference Laboratory for Tuberculosis Institut Pasteur of Bangui Bangui Central African Republic Faculty of Health Sciences University of Bangui Bangui Central African Republic Medical Laboratory Institute Pasteur of Bangui Bangui Central African Republic Epidemiology Unit Institute Pasteur of Bangui Bangui Central African Republic

Introduction: The Central African Republic is one of the 30 high Tuberculosis burden countries in the world, with an incidence of 540 cases per 100,000 population and a mortality of 91 deaths per 100,000 population. Since 2020, following WHO recommendations, the National Reference Laboratory for Tuberculosis has been using the Xpert® MTB/RIF assay as a first-line diagnostic test for the early detection of Drug Resistance Tuberculosis. The goal of this study was to ev.luate the contribution of the Xpert® MTB/RIF assay to the surv.illance of rifampicin resistance in new and prev.ously treated tuberculosis cases. Materials and Methods: The data relativ. to the Xpert® MTB/RIF assay carried out on v.rious categories of tuberculosis patients registered at the National Reference Laboratory for Tuberculosis in 2020 were analyzed retrospectiv.ly. The categories of tuberculosis patients were new cases, failed treatment cases, relapse cases, lost-to-follow-up cases and multidrug-resistant tuberculosis contact cases. Results: A total of 1404 tuberculosis patients were registered at the NRL-TB in 2020;the mean age was 39.2 years (2 - 90 years) and the male-to-female sex ratio was 1.16:1. Ov.rall, 32.7% (454/1404) prov.d infected with tuberculosis, of which 22.5% (102/454) cases showed resistance to rifampicin. The primary resistance rate was 9.1% (27/298) and the secondary resistance rate was 46.6% (75/161). Treatment failures and relapsed cases were significantly associated with rifampicin resistance (p 0.005). Conclusion: Large-scale use of Xpert® MTB/RIF, especially in the prov.nces of the Central African Republic, will help the Ministry of Health to better control Drug Resistance Tuberculosis in the country.

关键词： Xpert® MTB/RIF Assay Rifampicin Surv.illance CAR

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：